Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats

Neuroscience Research

Volumn 59, Issue 4, 2007, Pages 475-480

  Tanaka, Yu ^a   Omura, Tomohiro ^a   Fukasawa, Misako ^a   Horiuchi, Nobuko ^a   Miyata, Noriyuki ^a   Minagawa, Toshiya ^a   Yoshida, Shigeru ^a   Nakaike, Shiro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

20 HETE; Brain infarction; Functional outcome; Ischemic stroke; Neurological outcome; TS 011

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; N (3 CHLORO 4 MORPHOLIN 4 YL)PHENYL N' HYDROXYIMIDOFORMAMIDE; NEUROPROTECTIVE AGENT; TS 011; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN METABOLISM; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; ICOSANOID METABOLISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FORMAMIDES; HYDROXYEICOSATETRAENOIC ACIDS; ISCHEMIC ATTACK, TRANSIENT; MORPHOLINES; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; UP-REGULATION; VASODILATION;

EID: 35548994544     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.08.018     Document Type: Article

References (14)

1. Alonso-Galicia M., Hudetz A.G., Shen H., Harder D.R., and Roman R.J. Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. Stroke 30 (1999) 2727-2734
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., and Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17 (1986) 472-476
3. 2+ current. J. Physiol. 507 (1998) 771-781
4. Gebremedhin D., Lange A.R., Lowry T.F., Taheri M.R., Birks E.K., Hudetz A.G., Narayanan J., Falck J.R., Okamoto H., Roman R.J., Nithipatikom K., Campbell W.B., and Harder D.R. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ. Res. 87 (2000) 60-65
5. Gladstone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure. Lessons from neuroprotecive stroke trials and new therapeutic directions. Stroke 33 (2002) 123-2136
6. Harder D.R., Gebremedhin D., Narayanan J., Jefcoat C., Falck J.R., Campbell W.B., and Roman R. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am. J. Physiol. 266 (1994) H2098-H2107
7. Miyata N., Seki T., Tanaka Y., Omura T., Taniguchi K., Doi M., Bandou K., Kametani S., Sato M., Okuyama S., Cambj-Sapunar L., Harder D.R., and Roman R.J. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N′-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J. Pharmacol. Exp. Ther. 314 (2005) 77-85
8. Nagasawa H., and Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 20 (1989) 1037-1043
9. Omura T., Tanaka Y., Miyata N., Koizumi C., Sakurai T., Fukasawa M., Hachiuma K., Minagawa T., Susumu T., Yoshida S., Nakaike S., Okuyama S., Harder D.R., and Roman R.J. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 37 (2006) 1013-1307
10. Poloyac S.M., Zhang Y., Bies R.R., Kochanek P.M., and Graham S.H. Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J. Cereb. Blood Flow Metab. 26 (2006) 1551-1561
11. Rogers D.C., Campbell C.A., Stretton J.L., and Mackay K.B. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 28 (1997) 2060-2065
12. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
13. Stroke Therapy Academic Industry Roundtable (STAIR), 1999. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758.
14. Yu M., Cambj-Sapunar L., Kehl F., Maier K.G., Takeuchi K., Miyata N., Ishimoto T., Reddy L.M., Falck J.R., Gebremedhin D., Harder D.R., and Roman R.J. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur. J. Pharmacol. 486 (2004) 297-306